Dr. Graham Kelly Retires as Director, Marshall Edwards, Inc.
June 04 2007 - 12:21PM
PR Newswire (US)
WASHINGTON, June 4 /PRNewswire-FirstCall/ -- Professor Bryan
Williams, Chairman of Marshall Edwards, Inc., has advised that Dr.
Graham Kelly has retired as a Director of the Company. Professor
Williams noted the significant contribution made by Dr. Kelly to
the development of the drugs now licensed by Marshall Edwards. "His
contribution to the development of the anti-cancer compound
phenoxodiol in particular, is well known and acknowledged,"
Professor Williams said. About phenoxodiol: Phenoxodiol is being
developed as a therapy for late-stage, chemo-resistant prostate,
ovarian and cervical cancers. Phenoxodiol is an investigational
drug and, as such, is not commercially available. It is a
novel-acting drug that inhibits key pro-survival signaling pathways
operating via sphingosine-1-phosphate and Akt. Inhibition of these
pathways leads to prevention of phosphorylation of key
anti-apoptotic proteins such as XIAP. Loss of activity of these
proteins restores the ability of chemoresistant tumor cells to
undergo apoptosis in response to chemotherapy. The putative
molecular target for phenoxodiol is a tumor-specific protein,
accounting for the highly selective nature of the drug. About
Marshall Edwards, Inc.: Marshall Edwards, Inc. (NASDAQ:MSHL) is a
specialist oncology company focused on the clinical development of
novel anti-cancer therapeutics. These derive from a flavonoid
technology platform which has generated a number of novel compounds
characterized by broad ranging efficacy against a range of cancer
targets with few side effects. The unique combination of efficacy
and safety has been explained by their ability to target an enzyme
present on the surface of cancer cells, thereby inhibiting the
production of pro-survival proteins within the cell. Marshall
Edwards, Inc. has licensed rights from Novogen Limited
(NASDAQ:NVGN) to bring three oncology drugs - phenoxodiol, NV-196
and NV-143 - to market globally. Marshall Edwards, Inc. is majority
owned by Novogen, an Australian biotechnology company that is
specializing in the development of therapeutics based on a
flavonoid technology platform. Novogen, based in Sydney, Australia,
is developing a range of therapeutics across the fields of
oncology, cardiovascular disease and inflammatory diseases. More
information on phenoxodiol and on the Novogen group of companies
can be found at http://www.marshalledwardsinc.com/ and
http://www.novogen.com/. Under U.S. law, a new drug cannot be
marketed until it has been investigated in clinical trials and
approved by the FDA as being safe and effective for the intended
use. Statements included in this press release that are not
historical in nature are "forward-looking statements" within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. You should be aware that our actual
results could differ materially from those contained in the
forward-looking statements, which are based on management's current
expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to
successfully commercialize our product candidates; costs and delays
in the development and/or FDA approval, or the failure to obtain
such approval, of our product candidates; uncertainties in clinical
trial results; our inability to maintain or enter into, and the
risks resulting from our dependence upon, collaboration or
contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary rights to third
party patents and intellectual property to operate our business;
our inability to operate our business without infringing the
patents and proprietary rights of others; general economic
conditions; the failure of any products to gain market acceptance;
our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry
practice; and one-time events. We do not intend to update any of
these factors or to publicly announce the results of any revisions
to these forward-looking statements. DATASOURCE: Marshall Edwards,
Inc. CONTACT: David Sheon, +1-202-518-6321, ; Chris Naughton, 011
61 2 9878 0088, , both for Marshall Edwards, Inc. Web site:
http://www.marshalledwardsinc.com/ http://www.novogen.com/
Copyright
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024